{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:00:03Z","timestamp":1794711603993,"version":"4.9.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.euroneuro.2025.07.006","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T11:03:22Z","timestamp":1754478202000},"page":"3-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Risk of manic switch and suicidal outcomes in bipolar depression treated with esketamine: A one-year retrospective cohort study of 2126 patients"],"prefix":"10.1016","volume":"99","author":[{"given":"Ting-Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-1909","authenticated-orcid":false,"given":"Jheng-Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2025.07.006_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2012.12.009","article-title":"Sex differences in the antidepressant-like effects of ketamine","volume":"70","author":"Carrier","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.euroneuro.2025.07.006_bib0003","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMa Psychiatr."},{"issue":"7","key":"10.1016\/j.euroneuro.2025.07.006_bib0004","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2174\/1568026620666200131100316","article-title":"An update on glutamatergic system in suicidal depression and on the role of esketamine","volume":"20","author":"De Berardis","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euroneuro.2023.08.498","article-title":"Exploring the potential of Esketamine in the treatment of bipolar depression","volume":"77","author":"Dell'Osso","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0006","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.2147\/NDT.S273503","article-title":"Treatment-resistant bipolar depression: therapeutic trends, challenges and future directions","volume":"18","author":"Elsayed","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231202723","article-title":"Ketamine for bipolar depression: an updated systematic review","volume":"13","author":"Fancy","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0008","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpsychires.2019.01.010","article-title":"Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression","volume":"110","author":"Freeman","year":"2019","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.euroneuro.2025.07.006_bib0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"90","author":"Gastaldon","year":"2020","journal-title":"PsychOther Psychosom."},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.yrtph.2016.03.007","article-title":"Effects of gender on ketamine-induced conditioned placed preference and urine metabonomics","volume":"77","author":"Guo","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"15","key":"10.1016\/j.euroneuro.2025.07.006_bib0011","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMa"},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0012","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.bcp.2018.03.032","article-title":"Ketamine and ketamine metabolites as novel estrogen receptor ligands: induction of cytochrome P450 and AMPA glutamate receptor gene expression","volume":"152","author":"Ho","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.07.006_bib0013","article-title":"Bipolar depression: a review of treatment options","volume":"35","author":"Levenberg","year":"2022","journal-title":"Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2023.148375","article-title":"Antidepressant effects of repeated s-ketamine administration as NMDAR antagonist: involvement of CaMKII\u03b1 and mTOR signaling in the hippocampus of CUMS mice","volume":"1811","author":"Liu","year":"2023","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0015","article-title":"The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: a retrospective cohort study including 91,528 patients","author":"Liu","year":"2023","journal-title":"J. Infect."},{"issue":"3","key":"10.1016\/j.euroneuro.2025.07.006_bib0016","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bdi.13296","article-title":"Treating bipolar depression with esketamine: safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression","volume":"25","author":"Martinotti","year":"2023","journal-title":"Bipolar. Disord."},{"issue":"10265","key":"10.1016\/j.euroneuro.2025.07.006_bib0017","first-page":"1841","volume":"396","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord. Lancet"},{"issue":"1","key":"10.1016\/j.euroneuro.2025.07.006_bib0018","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41398-024-03033-4","article-title":"Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study","volume":"14","author":"Pan","year":"2024","journal-title":"Transl. Psychiatry"},{"issue":"23","key":"10.1016\/j.euroneuro.2025.07.006_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313098","article-title":"Variations in BDNF and their role in the neurotrophic antidepressant mechanisms of ketamine and esketamine: a review","volume":"25","author":"Pardossi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.euroneuro.2025.07.006_bib0020","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41380-018-0341-9","article-title":"NMDA 2A receptors in parvalbumin cells mediate sex-specific rapid ketamine response on cortical activity","volume":"24","author":"Picard","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"14","key":"10.1016\/j.euroneuro.2025.07.006_bib0021","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.euroneuro.2025.07.006_bib0022","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24m15376","article-title":"Efficacy and safety of ketamine\/esketamine in bipolar depression in a clinical setting","volume":"85","author":"Santucci","year":"2024","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2025.07.006_bib0023","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24m15376","article-title":"Efficacy and safety of ketamine\/esketamine in bipolar depression in a clinical setting","volume":"85","author":"Santucci","year":"2024","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2025.07.006_bib0024","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","article-title":"Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study","volume":"80","author":"Singh","year":"2016","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2025.07.006_bib0025","doi-asserted-by":"crossref","first-page":"259","DOI":"10.9740\/mhc.2021.07.259","article-title":"Intranasal esketamine use in bipolar disorder: a case report","volume":"11","author":"Skriptshak","year":"2021","journal-title":"Ment. Health Clin."},{"issue":"10","key":"10.1016\/j.euroneuro.2025.07.006_bib0026","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/14737175.2019.1640604","article-title":"Esketamine for treatment resistant depression","volume":"19","author":"Swainson","year":"2019","journal-title":"Expert. Rev. NeurOther"},{"issue":"5","key":"10.1016\/j.euroneuro.2025.07.006_bib0027","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S2215-0366(21)00084-5","article-title":"6-month neurological and psychiatric outcomes in 236\u2009379 survivors of COVID-19: a retrospective cohort study using electronic health records","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0028","unstructured":"TriNetX Accessed January 2, 2025. https:\/\/trinetx.com."},{"issue":"10","key":"10.1016\/j.euroneuro.2025.07.006_bib0029","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.4088\/JCP.v68n1002","article-title":"Self-reported history of manic\/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).(CME)","volume":"68","author":"Truman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.euroneuro.2024.06.005","article-title":"Cross-sectional studies: is pressing the pause button worth it in research?","volume":"85","author":"Vieta","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2025.07.006_bib0031","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0032","article-title":"Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks","volume":"53","author":"Wang","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.euroneuro.2025.07.006_bib0033","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.biopsych.2018.05.007","article-title":"AMPA receptor activation\u2013independent antidepressant actions of ketamine metabolite (S)-norketamine","volume":"84","author":"Yang","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2025.07.006_bib0034","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S2215-0366(23)00199-2","article-title":"Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis","volume":"10","author":"Yildiz","year":"2023","journal-title":"Lancet Psychiatr."},{"issue":"11","key":"10.1016\/j.euroneuro.2025.07.006_bib0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2025.07.006_bib0036","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.10208","article-title":"Neurocognitive effects of six ketamine infusions and the association with antidepressant effects in treatment-resistant bipolar depression: a preliminary study","volume":"8","author":"Zheng","year":"2020","journal-title":"PeerJ."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2500135X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X2500135X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T22:18:41Z","timestamp":1758061121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X2500135X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"alternative-id":["S0924977X2500135X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.07.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of manic switch and suicidal outcomes in bipolar depression treated with esketamine: A one-year retrospective cohort study of 2126 patients","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2025.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. and ECNP. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}